What do sources give as a spore based probiotic dose?
| Product | Strength | Adult dose on the label or insert |
|---|---|---|
| Probichew chew (B. coagulans) | 21 billion per serving, unit not stated on the label3 | 1 chew once or twice daily for adults, or as prescribed by a licensed medical practitioner3 |
| Enterogermina capsule (B. clausii) | 2 billion spores per capsule2 | 2 to 3 capsules per day2 |
| Enterogermina oral suspension (B. clausii) | 2 billion spores per 5 mL mini bottle4 | 2 to 3 mini bottles per day4 |
| BioPlus gummy (B. subtilis) | – | 2 gummies twice daily for adults, or as directed by a healthcare professional5 |
| Symbio Tilis Drops (Bacillus Subtilis 6X, a homeopathic product) | 6X as written on the label, not a CFU count6 | 5 drops orally, three times per week, with no age stated6 |
Strengths and label doses
The table is set at the top of the page
The DailyMed labels found for B. coagulans and B. subtilis are all dietary supplements or homeopathic products, though the Probichew and BioPlus labels are both marked "Dispensed by Prescription".35
What adult trials gave
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Madempudi 2019, B. coagulans Unique IS2, adults with IBS | 2 billion CFU or placebo1 | 136 randomised adults1 | 8 weeks, capsules daily1 |
| LeMoire 2025, B. coagulans Unique IS2, healthy adults with infrequent bowel movements | 2 billion colony forming units, or placebo7 | 144 healthy adults7 | 4 weeks, after a 2-week run-in7 |
| Kalman, Digestive Advantage Gas Defense Formula (B. coagulans GBI-30, 6086 with an enzyme blend) | 2.0 billion CFU per capsule, one capsule daily, or placebo8 | Sixty-one adults (30 on the product, 31 on placebo)8 | Four weeks8 |
| Garvey, B. subtilis BS50, healthy adults | 2 billion CFU per capsule, one capsule daily with the largest meal, or a maltodextrin placebo9 | Participants (n = 76)9 | 6 weeks9 |
| Hanifi 2015, B. subtilis R0179 | 0.1, 1.0 or 10×10⁹ cfu/capsule/day, or placebo10 | Healthy adults (n=81)10 | Four weeks10 |
| Wauters 2021, B. coagulans MY01 and B. subtilis MY02 blend | 2.5 billion CFU per capsule twice a day, or placebo11 | 68 adults with functional dyspepsia11 | 8 weeks, then an 8-week open-label extension11 |
| Soman 2019, SNZ TriBac blend of B. coagulans, B. clausii and B. subtilis | Dose not given in the text available; compared with placebo12 | Sixty adults with symptoms of GI discomfort12 | Outcomes on days 30 and 3712 |
In Hanifi 2015, faecal viable counts of B. subtilis R0179 rose with dose: 4.6, 5.6 and 6.4 log10 cfu/g across the three doses, against 1.1 on placebo.10
Doses used for H. pylori
The sources searched give no label or regulator dose for H. pylori. Registry entry NCT05483660 (planned for three hundred people) lists B. coagulans at 1.5 × 10^10 CFU with 15 g adult milk powder per time, three times daily, half an hour before meals; its status is unknown.13 In Zhang and colleagues' 2020 open-label pilot of 150 subjects with H. pylori, the B. coagulans group took tablets (350 mg × 3 tablets TID, no CFU stated) as monotherapy for 8 weeks; ITT eradication was 20% in that group, against 18% with C. butyricum alone and 26% with both together, and the authors report similar rates in the three groups.14
Timing, duration and cycles
The IS2 IBS trial (Madempudi 2019) gave its capsule after a meal, and the BS50 trial (Garvey) with the largest meal.19 In Perotti and colleagues' 2024 study of 24 healthy adults, one 24 g serving of SNZ1969 gummies (no less than a billion CFUs) was eaten once a day for two weeks, at least an hour from a meal.15 No trial in the sources searched compared times of day, or taking with versus without food.
Trial lengths in the sources run from two weeks to 8 weeks, with an 8-week open-label extension in one trial; the sources searched describe no cycles or on and off periods.1511411
Mixing powder and the syringe
No label in the sources searched gives a water volume or mixing steps for a spore based probiotic powder. The only mixing text found is in the Enterogermina suspension leaflet, which says to shake the mini bottle before use and take it as it is or dilute it in water or other beverages (e.g., milk, tea, orange juice).4 All the products found are oral and none is a U-100 syringe product, so no syringe mark applies.
Storage
Probichew is stored at 20°-25°C with excursions to 15°-30°C.3 BioPlus gives 20°–25°C and says to avoid excessive heat, light, moisture and over 85% humidity.5 The Enterogermina capsule insert gives not above 25°C; the suspension leaflet gives not above 30 °C.24
Storage after mixing a powder is not given in the sources searched.
Frequently asked questions
Can spore based probiotics go in hot food or drink?
The sources searched do not say whether a spore based powder may go in hot food or drink. The Enterogermina oral suspension leaflet says the mini bottle may be taken as it is or diluted in water or other beverages (e.g., milk, tea, orange juice), and gives no temperature for them.4
References
- PubMed Central. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults. 2019. pmc.ncbi.nlm.nih.gov
- Sanofi. ENTEROGERMINA®. sanofi.com
- DailyMed. Probichew. 2025. dailymed.nlm.nih.gov
- Sanofi. 940444 IST ENTEROG 2MLD/5ML BT10 M24 IN (Folder 4321471). sanofi.com
- DailyMed. BioPlus Bacillus Subtilis. 2026. dailymed.nlm.nih.gov
- DailyMed. TILIS 6X. 2026. dailymed.nlm.nih.gov
- PubMed. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial. 2025. pubmed.ncbi.nlm.nih.gov
- PubMed Central. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans -based product on functional intestinal gas symptoms. 2009. pmc.ncbi.nlm.nih.gov
- PubMed Central. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. 2022. pmc.ncbi.nlm.nih.gov
- PubMed. Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. 2015. pubmed.ncbi.nlm.nih.gov
- PubMed. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. 2021. pubmed.ncbi.nlm.nih.gov
- PubMed. A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort. 2019. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05483660: A Clinical Trial on the Efficacy of Gastric Probiotics in the Treatment of Helicobacter Pylori Infection. 2024. clinicaltrials.gov
- PubMed Central. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment. 2020. pmc.ncbi.nlm.nih.gov
- PubMed Central. Human in vivo assessment of the survival and germination of Heyndrickxia coagulans SNZ1969 spores delivered via gummy candies. 2024. pmc.ncbi.nlm.nih.gov